In one aspect, the invention relates to a non-lipidated and non-pyruvylated Neisseria meningitidis serogroup B subfamily A A12 polypeptide. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from Neisseria meningitidis serogroup B, and at least one conjugated capsular saccharide from a meningococcal serogroup.
1. An isolated non-lipidated and non-pyruvylated polypeptide consisting of the sequence set forth in SEQ ID NO: 66.
2. The polypeptide according to claim 1 , wherein the polypeptide is immunogenic.
3. The polypeptide according to claim 1 , wherein the polypeptide does not exhibit a mass shift of about +70 Da compared to the corresponding non-lipidated polypeptide as measured by mass spectrometry.
4. An immunogenic composition comprising an isolated non-lipidated and non-pyruvylated polypeptide consisting of the sequence set forth in SEQ ID NO: 66.
5. The composition according to claim 4 , further comprising an adjuvant.